Sep 14 2023 16 mins
Episode: Cytogenetics in CLL – The role of TP53
Dr Rosenquist and Dr Sarka Pavlova, an expert on TP53 aberrations, from the Masaryk University and University Hospital Brno, Brno, Czech Republic discuss one of the most important markers in CLL, TP53. The episode addresses questions such as; What do we mean with a TP53 aberration? How do we detect TP53 alterations? And what is the clinical impact of TP53 aberrations for patients with CLL?
References:
1. Malcikova J, et al. Leukemia. 2018;32:1070-80. 2. Patel K and Pagel JM. J Hematol Oncol. 2021;14:69. 3. Pospisilova S, et al. Leukemia. 2012;26:1458-61. 4. Malcikova J, et al. Leukemia. 2015;29:877-85. 5. Olbertova H, et al. BMC Cancer. 2022;22:137. 6. Malcikova J, et al. Blood. 2021;138:2670-85.
XN1309-08-23-ONC